PRF and PRP Growth Factor Release: How Long It Lasts
How do growth factor concentration and release timing compare between PRF and PRP?
Here's the honest version: PRP wins on peak concentration, PRF wins on how long the signal lasts, and both differences trace back to a single decision made before the tube ever reaches the centrifuge. If you're weighing the two, you're really choosing between one loud dose and a quieter one that keeps talking for days.
| Criteria | PRP | PRF |
|---|---|---|
| Anticoagulant | Sodium citrate or ACD-A | None at all |
| Spin | Second spin about 400 g to 3,000 g, optimum often cited near 1,000 g | 700 to 1,500 rpm for three to eight minutes |
| Platelet multiple | Three to six times whole blood | Scatters both below and above a well-made PRP |
| Release window | Over 95 percent out within the first hour | Still eluting at seven days, some protocols ten to fourteen |
PRP releases more than 95 percent of its pre-stored growth factors within the first hour at three to six times baseline platelet count, while PRF trades that peak for release that continues at seven days and in some protocols out to ten to fourteen days.
Which signalling proteins are actually being counted when a platelet concentrate is described as growth factor rich?
Alpha-granules hold roughly three hundred biologically active molecules, and marketing language almost never tells you which ones your follicles care about. Only a short list moves the needle on the scalp, and one member of that list cuts both ways.
- PDGF-BB: Drives dermal papilla proliferation and stabilises the capillary loop feeding the bulb.
- VEGF: The angiogenic half of the job, tied to earlier anagen entry and larger follicle diameter.
- IGF-1: The most direct anagen-prolonging signal, setting how long a follicle stays in growth phase.
- TGF-beta-1: Supports healing, but also implicated in catagen and miniaturisation.
Of the roughly three hundred molecules inside platelet alpha-granules, only PDGF, VEGF, TGF-beta-1, EGF, IGF-1 and basic FGF carry hair-relevant signal, and TGF-beta-1 is implicated in both repair and the catagen cascade of androgenetic alopecia.
How do the two preparation protocols produce different platelet and growth factor concentrations?
Everything downstream traces back to one choice made before the centrifuge is switched on: whether you let the blood clot. Once you see that decision, the rest of the protocol stops reading like a list of settings and starts reading like a consequence.
- Tube choice: PRP is drawn into citrate or ACD-A; PRF goes into plain glass or silica with no additive, so contact activation starts within seconds.
- First spin: PRP separates gently near 200 to 300 g for ten minutes to split red cells from plasma; PRF has to be spinning inside about sixty seconds of the draw.
- Concentration spin: PRP goes hard, roughly 400 g to 3,000 g for five to twenty minutes; PRF stays soft at 700 to 1,500 rpm, because a hard spin drives its platelets down into the red cell layer.
- What reaches the needle: PRP's pellet is resuspended in two to five millilitres; PRF's platelets stay enmeshed in fibrin, and part of that clot is never injected.
PRP's three-to-six-fold multiple comes from concentrating the same platelet mass into roughly a fifth of the original plasma volume, while PRF starts from a lower deliverable count by design because a meaningful share of its platelets is bound into clot material that never gets injected.
How much higher is the measured growth factor concentration in PRP than in PRF at the moment of injection?
At the needle, a well-prepared PRP genuinely does carry more protein per millilitre, and the gap isn't trivial. What's less obvious is how fast it stops being the number that decides anything.
| Measure | PRP | PRF |
|---|---|---|
| Platelet multiple | Three to six times baseline, seven to eight research-grade | About 1.5 to 2 times baseline in some studies, at or above a matched PRP in others |
| Supernatant at 15 to 60 minutes | Significantly higher across ELISA comparisons | Matches or exceeds PRP on individual factors in some assays |
| Volume injected | Smaller, platelet-poor plasma discarded | Comparable or larger, nothing discarded |
PRP's per-millilitre advantage at fifteen to sixty minutes is real but not linear with platelet count, since harder spinning damages a fraction of the platelets and degrades part of their cargo, and PRF's larger injected volume narrows the gap in total delivered protein.
Why does the fibrin architecture in PRF turn a single burst of growth factors into a release that continues for days?
The timing difference is structural, not chemical. Clotting slowly at physiological thrombin builds a loose, flexible three-dimensional mesh instead of the dense network that rapid activation creates. Release then stops being about how fast the platelets empty and becomes about how fast that scaffold breaks down.
- First hours: A modest burst as free and surface-bound protein comes off the mesh.
- Day three to day seven: A sustained plateau, with PDGF, TGF-beta-1 and VEGF still measurable in the medium.
- Day ten to fourteen: Denser membrane protocols keep eluting as plasmin-mediated fibrinolysis dismantles the network.
Fibrin binds VEGF, FGF-2 and TGF-beta through their heparin-binding domains and physically traps platelets and leukocytes, so PRF's cumulative release can exceed a one-off PRP total, though scalp tissue with blood flow and active plasmin clears a fibrin deposit faster than a static culture well and shortens the real window.
How does the decision to use an anticoagulant change what the platelets are able to release?
Calcium isn't only a clotting cofactor. It's the second messenger platelets use for granule fusion and release, so the moment you chelate it you've changed what those cells can do, not just when they can do it.
PRF's additive-free route buys physiological activation but imposes a hard sixty second window from venepuncture to centrifuge, because coagulation begins in the tube on draw and a clot that sets into the wrong geometry can't be recovered.
What do the two release curves imply for how far apart treatment sessions should be spaced?
If release kinetics set your calendar, PRP and PRF would look nothing alike on it. They don't, and the reason is that the hair cycle sets the pace rather than the pharmacokinetics.
Both formats converge on an induction course of three to four sessions spaced four to six weeks apart followed by maintenance every four to six months, because no release curve measured in days can outrun a hair cycle measured in quarters.
Does the clinical evidence in hair restoration favour a concentrated burst or a slow release?
Anyone telling you this is settled is running ahead of the data. The head-to-head literature is small, short, and measured in ways that don't line up between studies, and that's a different problem from the two products genuinely performing the same.
- Trial size: A handful of head-to-head studies, most with a few dozen participants.
- Follow-up: Commonly three to six months, which says nothing about durability.
- Findings: Some report a modest PRF advantage on density or terminal hair count, others no significant difference.
- The missing piece: No clean demonstration that a six-fold PRP outperforms a three-fold one.
Neither format is proven superior, since the head-to-head trials in androgenetic alopecia are small and follow patients only three to six months, so the choice today rests more on the operator's protocol discipline than on the acronym.
What does the leukocyte and fibrin scaffold in PRF contribute beyond the growth factors themselves?
Calling PRF a slow-release PRP undersells what the clot is carrying. The low-speed protocols keep the white cells on purpose, and the fibrin is doing a job of its own rather than just holding protein.
- Leukocytes: Neutrophils and monocytes add their own cytokines plus antimicrobial activity at the injection site.
- Provisional matrix: The fibrin gives cells something to migrate along, which is why membranes work as grafting adjuncts.
- CD34 positive cells: Low-speed preparations concentrate a small progenitor population, more so in concentrated-growth-factor protocols.
- Fully autologous: No anticoagulant and no exogenous thrombin, so bovine thrombin sensitisation concerns fall away.
PRF's retained leukocytes are a real trade-off rather than a settled advantage, since leukocyte-rich preparations are associated with more post-injection inflammation and soreness, deliberately depleted in many intra-articular protocols but usually considered tolerable or even helpful in the scalp.
Where does concentration stop predicting results, and what goes wrong when it is treated as the only measure?
This is where a clinic's headline number can quietly work against you. Growth factor signalling is receptor-mediated and saturable, so once the PDGF and VEGF receptors on dermal papilla cells are occupied, more ligand buys nothing and sustained high levels push those receptors to internalise and down-regulate.
Scaling the whole granule cargo upward also scales TGF-beta-1, one of the mediators through which dihydrotestosterone is thought to push follicles into catagen, and patient variables including baseline platelet count, degree of miniaturisation, smoking, anaemia and thyroid status dwarf the difference between the two preparations.
